Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

DnaJC28 Inhibitors

The classification of DnaJC28 inhibitors designates a distinctive cohort of chemical compounds with a remarkable aptitude for intricately modulating the complex machinery of the DnaJC28 protein. Amid the dynamic milieu of cellular constituents, DnaJC28 occupies a notable niche within the expansive repertoire of DnaJ proteins, a family renowned for their pivotal roles in orchestrating essential cellular processes, including the meticulous folding of proteins and the adroit management of cellular responses to stressors. What sets these inhibitors apart is their capacity for precision-guided interaction, which extends to either the catalytically active pocket or specific binding domains intricately situated within the spatial architecture of the DnaJC28 protein. By establishing these molecular dialogues, the inhibitors wield an extraordinary influence over the intrinsic behavior of DnaJC28. This intricate interplay can potentially reverberate across a spectrum of cellular activities, encompassing the finesse of protein-protein interactions within the intricate matrix of molecular networks, the judicious orchestration of elaborate protein folding pathways that ultimately govern functional conformations, or the oversight of multifaceted functions that find their nexus in the domains of DnaJC28. As researchers delve into the nuanced landscape of DnaJC28 inhibitors, a profound vista unfolds-a panorama of insights into the cellular symphony orchestrated by regulatory mechanisms. This scientific pursuit unravels the enigmatic roles that DnaJC28 plays, akin to deciphering a complex musical composition note by note. In doing so, we contribute not only to the tapestry of fundamental science but also to the broader narrative of how cells finely calibrate their actions. The journey through DnaJC28 inhibitors serves as an expedition into the intricacies of cellular choreography, where precision interactions lead to nuanced outcomes and where deciphering the language of molecules empowers us to unlock the secrets of cellular operations.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Imatinib inhibits tyrosine kinases such as BCR-ABL, c-KIT, and PDGFR, suppressing the aberrant signaling that drives cancer growth. It interrupts cell division and promotes apoptosis in cancer cells.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Sorafenib is a multi-kinase inhibitor that interferes with RAF kinases and VEGFR-2, slowing tumor growth and inhibiting angiogenesis.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$85.00
$132.00
$287.00
$495.00
$3752.00
42
(0)

Erlotinib blocks the activity of EGFR by competitively binding to its ATP-binding site, thus preventing downstream signaling and growth stimulation.

CH5424802

1256580-46-7sc-364461
sc-364461A
5 mg
50 mg
$191.00
$902.00
(0)

Alectinib specifically inhibits ALK, a receptor tyrosine kinase, to suppress the signaling pathways involved in cell survival and proliferation, mainly in non-small cell lung cancer.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$116.00
$330.00
$510.00
$816.00
$1632.00
10
(0)

ABT-199 disrupts the BCL-2 protein's anti-apoptotic function, leading to apoptosis induction in cancer cells, particularly effective against chronic lymphocytic leukemia (CLL).

Ribociclib

1211441-98-3sc-507367
10 mg
$450.00
(0)

Ribociclib also targets CDK4/6, hindering cell cycle progression in hormone receptor-positive breast cancer and enhancing the efficacy of endocrine therapies.

Abemaciclib

1231929-97-7sc-507342
10 mg
$110.00
(0)

Abemaciclib inhibits CDK4/6, regulating cell cycle progression and replication in HR-positive, HER2-negative advanced breast cancers.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

Ruxolitinib is a JAK1/2 inhibitor that interrupts cytokine signaling pathways in myeloproliferative disorders, reducing inflammation and controlling abnormal cell growth.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

Ibrutinib targets Bruton's tyrosine kinase (BTK), impeding B-cell receptor signaling and promoting apoptosis in B-cell malignancies, notably effective in chronic lymphocytic leukemia.